Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015, Article ID 817578, 4 pages
http://dx.doi.org/10.1155/2015/817578
Case Report

Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

1Department of Hematology and Oncology, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA
2Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue J3-4, Cleveland, OH 44195, USA

Received 16 July 2015; Accepted 30 September 2015

Academic Editor: Raffaele Palmirotta

Copyright © 2015 Bo Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. I. Rini, S. Halabi, J. E. Rosenberg et al., “Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2137–2143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. X.-L. Chen, Y.-H. Lei, C.-F. Liu et al., “Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis,” PLoS ONE, vol. 8, no. 6, Article ID e66721, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. R. J. Motzer, T. E. Hutson, P. Tomczak et al., “Sunitinib versus interferon alfa in metastatic renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 2, pp. 115–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Motzer, T. E. Hutson, D. Cella et al., “Pazopanib versus sunitinib in metastatic renal-cell carcinoma,” The New England Journal of Medicine, vol. 369, no. 8, pp. 722–731, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Escudier, T. Eisen, W. M. Stadler et al., “Sorafenib in advanced clear-cell renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 2, pp. 125–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Schmidinger, C. C. Zielinski, U. M. Vogl et al., “Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5204–5212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. B. I. Rini, B. Escudier, S. Hariharan et al., “Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma,” Clinical Genitourinary Cancer, 2015. View at Publisher · View at Google Scholar
  8. D. J. Stewart, M. J. B. Kutryk, D. Fitchett et al., “VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial,” Molecular Therapy, vol. 17, no. 6, pp. 1109–1115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Khurana, M. Simons, J. F. Martin, and I. C. Zachary, “Role of angiogenesis in cardiovascular disease: a critical appraisal,” Circulation, vol. 112, no. 12, pp. 1813–1824, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Shiojima, K. Sato, Y. Izumiya et al., “Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure,” Journal of Clinical Investigation, vol. 115, no. 8, pp. 2108–2118, 2005. View at Publisher · View at Google Scholar · View at Scopus